本文選題：釕復(fù)合物 + 泌尿系腫瘤　； 參考：《實用醫(yī)學(xué)雜志》2017年22期

【摘要】：金屬鉑類藥物作為抗腫瘤藥物已經(jīng)廣泛應(yīng)用于臨床,然而鉑類藥物存在許多缺點,比如明顯的毒副作用、藥物耐受性以及低水溶性,產(chǎn)生了尋找替代含過渡金屬的抗腫瘤藥物的需要。為了克服這些缺點,金屬釕復(fù)合物應(yīng)運而生并且展現(xiàn)出良好的前景。金屬釕復(fù)合物在體內(nèi)和體外都顯示了良好的藥物學(xué)性能,同時具有低毒和良好選擇性,并且能克服順鉑耐受的缺點。因此,針對金屬釕復(fù)合物的良好抗腫瘤性能,有望改善泌尿系腫瘤的治療現(xiàn)狀。本文主要對近年來金屬釕復(fù)合物在泌尿系腫瘤中的研究進(jìn)展進(jìn)行綜述。
[Abstract]:Metal platinum drugs have been widely used in clinic as antitumor drugs. However, platinum drugs have many disadvantages, such as obvious side effects, drug tolerance and low water solubility. There is a need to find alternative anti-tumor drugs containing transition metals. In order to overcome these shortcomings, ruthenium complexes emerge as the times require and show good prospects. Ruthenium complexes exhibit good pharmacological properties in vivo and in vitro, low toxicity and selectivity, and can overcome the shortcomings of cisplatin tolerance. Therefore, the excellent anti-tumor performance of ruthenium complexes is expected to improve the current status of urological tumor treatment. In this review, the recent advances in the research of ruthenium complexes in urological tumors were reviewed.
【作者單位】： 廣東醫(yī)科大學(xué)附屬醫(yī)院泌尿外科;
【基金】：國家自然科學(xué)基金資助項目(編號:8140102155)
【分類號】：R737.1
，

本文編號：1827510